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ABSTRACT
Objective: This study aimed to use qualitative
methodology to understand the current role of
community pharmacists in limiting the use of
antipsychotics prescribed inappropriately for
behavioural and psychological symptoms of dementia.
Design: A qualitative study employing focus groups
was conducted. Data were analysed using thematic
analysis.
Setting: 3 different geographical locations in the
England.
Participants: Community pharmacists (n=22).
Results: The focus groups identified an array of
factors and constraints, which affect the ability of
community pharmacists to contribute to initiatives to
limit the use of antipsychotics. 3 key themes were
revealed: (1) politics and the medical hierarchy, which
created communication barriers; (2) how resources
and remit impact the effectiveness of community
pharmacy; and (3) understanding the nature of the
treatment of dementia.
Conclusions: Our findings suggest that an
improvement in communication between community
pharmacists and healthcare professionals, especially
general practitioners (GPs) must occur in order for
community pharmacists to assist in limiting the use of
antipsychotics in people with dementia. Additionally,
extra training in working with people with dementia is
required. Thus, an intervention which involves
appropriately trained pharmacists working in
collaboration with GPs and other caregivers is required.
Overall, within the current environment, community
pharmacists question the extent to which they can
contribute in helping to reduce the prescription of
antipsychotics.
BACKGROUND
Dementia has an estimated global prevalence
of over 35 million people.1 Dementia affects
over 800 000 in the UK.2 People with
dementia, like other older people, may be
prescribed complex medication regimens,
increasing the risk of drug interactions and
adverse events.3 4 Of particular concern is the
potentially inappropriate prescribing of anti-
psychotic medication in people with demen-
tia, which has been associated with 1800
deaths annually due to an increased risk of
stroke and pneumonia.5 While a recent
national audit identiﬁed that antipsychotic
prescriptions for people with dementia
reduced by 52% between 2008 and 2011, this
audit did not collect data on harm and relied
on the accuracy of the dementia registers.6
Limiting the use of antipsychotics in
dementia is a key public health objective and
a key recommendation of the Banerjee
report.5 The National Dementia Strategy
highlighted the role of pharmacist-led medi-
cation review, which could be implemented
by community pharmacists.5 Furthermore,
both the Royal Pharmaceutical Society tool
kit and guidance from Alzheimer’s Society
have identiﬁed a potential role for commu-
nity pharmacists.7 8 While the National
Dementia Strategy only applies to England,
Strengths and limitations of this study
▪ As far as we are aware, this is the only published
study that has investigated the views of commu-
nity pharmacists on whether they can contribute
to the initiative to limit the use of antipsychotics.
▪ The results require triangulation with general
practitioners, and people with dementia and their
carers.
▪ Participants were recruited from three different
geographical locations in the UK and data satur-
ation was achieved.
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there is a need to limit the use of antipsychotics across
the UK.7 8
While there is a signiﬁcant literature on pharmacists
providing clinical services in general, there is little on
services speciﬁcally in dementia care.9–21 One cross-
sectional survey explored the knowledge, experience
and attitudes of community pharmacists on pain experi-
enced by people with dementia and its management.12
Another study found that a pharmacy-led programme
could support withdrawing antipsychotics in people with
dementia; however, this clinical service was delivered by
a specialist dementia care pharmacist.20 There is also a
current cluster randomised controlled trial in the
Netherlands which aims to improve psychotropic usage
in nursing home residents with dementia.9 The interven-
tion is a structured multidisciplinary medication review
involving pharmacists, physicians and nurses, and educa-
tion delivered within the nursing home.9
There may be signiﬁcant barriers to community phar-
macists delivering such a role,9 14 21 and outcomes from
pharmacy-led interventions have been variable.11 13 14
Community pharmacists do not usually have full access
to the patients’ clinical histories and the Summary Care
Record may not contain enough information.14 22
Commonly, the prescribing decision rests with the
general practitioner (GP) which means community
pharmacists can only make clinical recommendations,
and indeed in some cases may not even know if their
suggestions were acted on.14 Furthermore, GPs may not
believe that community pharmacists can add clinical
value to chronic disease management.23 This study used
qualitative methodology to examine the current role of
community pharmacists with respect to the use antipsy-
chotics in behavioural and psychological symptoms of
dementia (BPSD).
AIMS AND OBJECTIVES
Aim
To understand the current role of community pharma-
cists in limiting the use of antipsychotics prescribed
inappropriately for BPSD.
Objectives
To understand the opinions and experience of commu-
nity pharmacists, focusing on their knowledge and opi-
nions of the national initiative.
To identify barriers and facilitators to community
pharmacists developing a role in this clinical area.
METHODS
Design
An exploratory study was conducted which utilised a
semistructured schedule to guide discussions in focus
groups. Three focus groups were facilitated by LA, a
health psychologist in training. They were audio-
recorded, transcribed verbatim and analysed using the-
matic analysis.
Participants
Three focus groups were held in three different geo-
graphical locations in England: the North East (NE),
West Midlands (WM) and South East (SE; precise areas
have been kept anonymous). This ensured a wide geo-
graphical representation and the possibility for a wide
range of experiences.
The criteria for inclusion in the study were that all
participants worked or had worked, whether full or part
time, as a community pharmacist.
Sampling and recruitment
Participants were recruited through local pharmaceut-
ical networks. The study was advertised on the
relevant, geographically speciﬁc Local Pharmaceutical
Committee (LPC) websites, which explained what taking
part in the research involved the criteria the individual
had to meet in order to do so, as well as the date the
focus group would occur. Purposive sampling was origin-
ally employed. This developed into a snowball sample as
data were gathered, and contacts were asked to suggest
other community pharmacists who might be willing to
take part in this study. The contact details of LA were
provided on the advert, and potential participants were
at liberty to contact via email to express interest. An
email with an information sheet, consent form and
expression of interest form would be attached and
emailed back to these interested individuals, and after
consenting, LA gave the venue details and time of the
focus group to the participants. Written consent was
obtained from all participants prior to data collection.
Data collection
Ethics approval was granted by the appropriate
University Research Ethics Committee in June 2013 and
the study was conducted between September and
November 2013. Each focus group was co-facilitated by
an experienced pharmacist to support LA with any spe-
cialist pharmacy terminology. For the focus group to
take place, between 4 and 10 participants were required.
The interview schedule consisted of open-ended ques-
tions to avoid leading participants’ responses (see online
supplementary appendix 1). Prompts were included in
the schedule and were employed if required.
Data analysis
The focus groups were recorded and the recordings
transcribed (using a transcription service). These tran-
scripts were analysed using thematic analysis (coded by
LA). Thematic analysis was used because it is a ﬂexible
method which is able to provide a detailed and complex
account of qualitative data, and is widely used in health-
care research.24 IDM and RS also independently
reviewed the transcripts and the coding by LA. Any dis-
agreements over interpretation of the data were dis-
cussed between LA, IDM and RS until consensus was
reached. Deviant case analysis was also performed
in order to reduce any bias. Three key concepts were
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elicited from the data with subthemes within these
three themes.
RESULTS
Twenty-two participants were recruited (14 females and
8 males): NE: 6 (4 females, 2 males), WM: 5 (1 females,
4 males), SE: 11 (9 females, 2 males; for further demo-
graphic information see online supplementary appendix
2). It was not possible to state the number of pharma-
cists approached and the number who declined due to
the method used to recruit participants.
When discussing the role community pharmacists have
in reducing the prescription of antipsychotics in demen-
tia, the focus groups revealed an undercurrent of
concern as to whether this was manageable within the
constraints of their role, as well as an array of factors
which would have to be considered and altered. Three
themes were revealed: (1) politics and the medical hier-
archy; (2) how resources and remit impact the effective-
ness of community pharmacy; and (3) understanding
the nature of the treatment of dementia.
Theme 1: politics and the medical hierarchy
Similar discussion between groups was elicited, which
concentrated on the relationship of community pharma-
cists with GPs. This was expressed in a way that suggested
feelings of inferiority towards GPs, which in turn created
a barrier in communication. This was perceived to be
perpetuated by the attitude of GPs, who the participants
felt, were unwilling to listen to their perspective:
Even if you say it in the right manner, you still haven’t
got any real authority. So he can tell you whatever he
wants. (WM2)
Community pharmacists believed that they needed to
exert considerable effort to improve their working rela-
tionship, but perceived a lack of recognition of their job
status:
Tact and diplomacy are required but, as you say, you are
quite likely to get a message back saying, “You are neither
a consultant nor a prescriber, so toe the line. (WM5)
This idea that, because community pharmacists are not
GPs or consultants, community pharmacists believed that
others thought their opinions lacked validity, which
affected their interactions with GPs. The above extract also
suggests that even if GPs are polite with community phar-
macists, they may still be interpreted as patronising,
demonstrated through the GPs’ questioning, which under-
mined both the expertise of community pharmacists and
the legitimacy of their concern for the patient’s welfare.
A level of self-doubt and, indeed, fear was portrayed
when the participants considered their own remit as pro-
fessionals in relation to communication with GPs:
And I wanted to ask you, just to expand this and I don’t
mean this disrespectfully at all…but would you also be
fearful about your skill set if the GP said to you, OK, let’s
withdraw it. Tell me how to do it. (SE3)
Yes. Absolutely. Yes. (SE—general consensus)
This signiﬁed a general lack of self-efﬁcacy within the
profession and had a direct impact on the self-efﬁcacy of
the community pharmacists.
This lack of communication between community phar-
macists and GPs was further exacerbated when partici-
pants explained how they had contacted GPs and in
some cases, consultants, only to never receive a reply.
Even when the community pharmacists had successfully
contacted GPs, GPs had not altered their practice based
on the concerns presented to them:
I’ve never succeeded in getting a GP to say, “OK, we’ll
scrub that”. (WM5)
All of the above paints a compelling picture of com-
munity pharmacists not having their voices heard, or the
voice they once had being silenced by negative experi-
ences. This is further impaired by the lack of resources
that community pharmacists have access to.
Theme 2: how resources and remit impact the effect-
iveness of community pharmacy
There was an overall consensus across the groups that
community pharmacists were under-resourced and
without adequate power within the existing parameters
of their work. This included no direct access to patients’
records, which they believed was vital for any role in lim-
iting the use of antipsychotics:
We don’t have access to notes in terms of their records.
(SE11)
This limited their effectiveness in this area and
demonstrates that community pharmacists do not yet
feel suitably trained in the specialised area of treatment
of BPSD:
We, as pharmacists, well currently we haven’t been
trained unless you are a specialist, in behavioural
changes. We have no equipment on that at all…I would
feel at the moment totally out of my depth. (SE10)
Participants reported feeling signiﬁcant uncertainty
about the remit of their profession with regard to this
initiative:
It’s always difﬁcult to know what is appropriate and
inappropriate in psychotic medicine. (NE2)
However, community pharmacists already manage
busy schedules and the feasibility of implementing
increased scope needs to be investigated:
One of the major obstacles is time…you haven’t got the
time to put that into practice. (WM5)
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The idea of introducing another responsibility into
this role raises challenges, not least with respect to
community pharmacists’ professional identity, compe-
tency and stretched resources. Furthermore, in the
absence of an incentive for community pharmacists to
take on additional work, it is unlikely that this role will
develop:
If you were reimbursed more appropriately for patients
who take a lot more time to be dealt with. (NE4)
More fundamentally, awareness of the current object-
ive to reduce the use of antipsychotics in people with
dementia needs to be raised among community
pharmacists:
I wasn’t aware of any speciﬁc initiative. (WM5)
Well, I know there was a call to action some time ago,
several years ago I think, wasn’t it, I think. (SE6)
Theme 3: anomalies and uncertainty: understanding
the nature of the treatment of dementia
The community pharmacists also questioned whether
or not it was appropriate to query the prescribing of
antipsychotics in people with dementia. They believed
that there was a need to balance the safety of the
patient and others versus the side effects of
antipsychotics.
This patient is going crazy, ﬂying off the walls, it’s in the
patient’s best interest to sort her out because…you have
to balance the risk and beneﬁt. (WM3)
This again portrays the sense of uncertainty about
what is best for the patient and the ambiguity experi-
enced by community pharmacists partly due to the lack
of access to information. Furthermore, if GPs cannot be
contacted, the community pharmacist must either
dispense the drugs or not dispense them until they have
managed to reach the GP and discussed the prescription
with the GP; this may be difﬁcult if the community
pharmacist does not know the patient, or has not
spoken to the patient’s family. In addition, questions
arose surrounding the issue of consent and who has
permission to give it when confronted with dementia
treatment issues:
So if it’s a third party, unless they are caught in the
ethical gap, so like, you need to discuss it with the person
themselves. So if the person is in a position where they
can’t come in to your pharmacy and you can’t go there
to discuss it with them. (SE3)
With this uncertainty combined with the pressures
identiﬁed in all the themes, the community pharmacists
appeared to neglect dementia care:
Dementia gets put on the too difﬁcult to do pile. (SE3)
DISCUSSION
All extracts presented paint a complex picture of the
heterogeneous nature of dementia and the multifaceted
issues related to its treatment. We observed a negative
cycle within community pharmacists’ accounts which
seemed to stem from a lack of professional conﬁdence,
which developed a sense of inferiority, which was exacer-
bated by a lack of training and challenging symbiotic
relationships with GPs.25 This problem is further aggra-
vated by not having access to patient records, lack of
ﬁnancial incentives and current workload issues. The
Department of Health and the Royal Pharmaceutical
Society highlight the role that community pharmacists
could play in helping reduce the prescription of antipsy-
chotics.5 7 However, the extent to which community
pharmacists feel they can contribute to this initiative is
limited.
People with dementia may be a greater risk of
medication-related adverse events due to the impact of
cognitive impairment.26 27 Like other research, on the role
of community pharmacists in general, we found that isola-
tion, poor integration into the healthcare team, being
viewed as ‘shopkeepers’ re-enforcing a sense of inferiority
and lack of access to records inhibit community pharma-
cists from developing a clinical role.14 28–33 It is unclear
from this investigation whether or not the attitude of GPs
is a primary cause, a contributing factor or simply a conse-
quence of community pharmacists’ low self-efﬁcacy.
While, as far as we are aware, this is the ﬁrst published
study that has investigated the involvement of commu-
nity pharmacists in supporting the appropriate use of
medication to treat BPSD; other research has found bar-
riers in other speciﬁc dementia syndromes, such as pain,
suggesting that dementia care is an area that community
pharmacists generally ﬁnd particularly challenging.12
Our research also conﬁrms some of the issues identiﬁed
by the Royal Pharmaceutical Society.7 The pharmacist
may not be able to rely on the person with dementia as
an historian; thus, there is greater reliance on the clin-
ical record. The public may be particularly reluctant to
trust pharmacists to deliver services that are perceived as
risky, such as the treatment of BPSD.30 Finally, we found
that accessible training to improve the skills in the phar-
macy workforce, sufﬁcient time and a collaborative
multidisciplinary approach are required to develop the
community pharmacist role in this area, echoing previ-
ous research.14 17 31 34 35
Limitations of the study
Qualitative methods often rely on smaller sample sizes to
allow for participant accounts to be analysed in sufﬁcient
detail for the results to be meaningful. The participants
in this study were a mix of ages and experiences (see
online supplementary appendix 2 for more information)
recruited from three different geographical locations in
the UK, which was to the study’s beneﬁt. While data sat-
uration was achieved, the ﬁndings require conﬁrmation.
Another limitation to this study is the lack of
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triangulation of results from community pharmacists
with GPs and people with dementia and their carers.
Implications for practice
This research suggests that current policy initiatives to
develop a clinical role for community pharmacists in
dementia care are likely to be unsuccessful. Perceptions of
community pharmacy held by key stakeholders need to
change in general.29 30 36 A more collaborative approach
with access to clinical records is required. However, con-
cerns have been expressed that community pharmacies
may use the National Health Service (NHS) data for com-
mercial reasons,37 and the general public may be reluctant
to allow access to health records unless the need for this
access is clearly explained.33 If community pharmacists
and GPs could develop an effective working relationship,
link with specialist services, via a collaborative medication
review, this could limit the inappropriate use of psychotro-
pics to treat BPSD.21 Joint training with GPs and pharma-
cists is one potential promising avenue; in addition to
developing the clinical skills of community pharmacists,
the training could be a stepping stone towards a more col-
laborative approach to medication optimisation.14 31 38
Future research
Our results suggest that any effective intervention, to
reduce the prescription of antipsychotics in people with
dementia, is likely to require the input of specially
trained pharmacists working collaboratively with
GPs, community pharmacists, patients and carers.
Furthermore, it would require expertise from Health
Psychologists to ensure any proposed behaviour change
at the systemic level has a sound basis in evidenced
behavioural science.39 40 Authors of this paper are con-
ducting two research projects in this area. First, we have
received funding from Pharmacy Research UK to study
the role of community pharmacists in medication man-
agement in dementia. Second, we hold an National
Institute for Health Research (NIHR) grant (RfPB
reference number: PB-PG-0613-31071) to investigate the
feasibility of trialling a combined pharmacy and health
psychology informed intervention to limit the use of psy-
chotropic medication to treat BPSD and to prepare care
home staff to care effectively for people with dementia
exhibiting challenging behaviour.41 The intervention
plans to use a collaborative model with experts from sec-
ondary care supporting primary care. Research should
also investigate methods to improve collaboration
between community pharmacists and GPs, in general.
CONCLUSION
This qualitative study found that community pharmacists
question the extent that they can contribute to national
objectives to reduce the prescription of antipsychotics
for people with dementia. The pharmacists interviewed
believed that issues such as suboptimal teamwork
between community pharmacists and GPs, a lack of full
access to records and limited training need to be
addressed. These barriers may have a greater impact in
dementia care, and therefore the ability of community
pharmacists to contribute to care in this environment
may be especially limited. A more collaborative
approach to care, which allowed community pharmacists
access to clinical records, along with appropriate train-
ing could start to address some of the issues raised.
However, until these issues are addressed, community
pharmacists will lack the knowledge and information,
and therefore the conﬁdence required to develop any
meaningful role in this aspect of dementia care.
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